Agreement grants Freeline rights to develop and commercialise AAV gene therapies using cardiac protein genes identified by Forcefield London UK, 4 April 2023 Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, and Freeline Therapeutics have entered into an exclusive patent and…